Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Use Survey of Trastuzumab Biosimilar (Daiichi Sankyo) in HER2-positive Gastric Cancer
jRCT1080224770Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab in gastric cancer (GC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall response rate within 8 months. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCT1080224770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224770.